Trending Stocks By Analyst's for this Week
Aardvark Therapeutics was rated Buy by HC Wainwright, with a target price of $40.00. AbbVie received a Buy rating from Morgan Stanley, with a price target of $250.00. Aemetis had its target raised by UBS Group, reaffirming a Buy rating and lifting the price from $2.20 to $3.00. AeroVironment was initiated with a Buy rating by The Goldman Sachs Group, targeting $301.00. Affirm had its target raised by Barclays and maintained an Overweight rating, with the price increased from $67.00 to $80.00. Agnico Eagle Mines received an Outperform initiation from Raymond James Financial, with a target price of $130.00. Agree Realty was reiterated as Market Perform by JMP Securities. Air Products and Chemicals was reiterated with a Buy rating by Citigroup, increasing the target from $310.00 to $320.00. Alnylam Pharmaceuticals had its target raised by Wells Fargo & Company, maintaining an Equal Weight rating, and the price increased from $287.00 to $333.00. American Healthcare REIT was initiated at Sector Outperform by Scotiabank, with a target of $42.00. Amgen received a Buy rating from TD Cowen, with a price target of $389.00. Amgen was rated Hold by Morgan Stanley, with a target of $330.00. Amplify Energy was initiated with a Buy rating by Alliance Global Partners, with a price target of $6.00. Anglogold Ashanti PLC received a Buy rating from Roth MKM, with a target price of $54.00. Antero Resources was rated Hold by Citi, with a target of $45.00. Aramark was maintained at Equal Weight by Morgan Stanley, with a price target increase from $42.00 to $44.00. Argenx Se also received a Buy rating from Wells Fargo, targeting $741.00. Argenx Se was rated Buy by Citi, with a target price of $803.00. ARM had its target raised by Guggenheim, keeping a Buy rating and lifting the price from $147.00 to $187.00. Aurinia Pharmaceuticals was rated Buy by both Leerink Partners and TD Cowen, with targets of $10.00 and $11.00, respectively. Aytu BioPharma was given a Buy initiation by Ascendiant Capital Markets, with a target price of $12.00. B2Gold was initiated with an Outperform rating by Raymond James Financial, targeting $4.50. Baker Hughes Company was rated Buy by Wells Fargo, aiming for $50.00. Beazer Homes USA was initiated as Neutral by B. Riley, with a target of $23.00. BioCryst Pharmaceuticals had its Outperform rating reiterated by Royal Bank of Canada, with a target of $13.00. BioCryst received a Buy rating from BofA Securities, with a target of $15.00. Boeing was rated Buy by Citi, with a price target of $220.00. Boyd Gaming had its Outperform rating reaffirmed by Raymond James Financial, and its target raised from $81.00 to $85.00. BridgeBio Pharma had its target raised by Wells Fargo & Company, keeping an Overweight rating and raising the price from $67.00 to $76.00. BridgeBio Pharma received a Buy rating from Raymond James, with a price target of $57.00. Brookfield Asset Management was initiated with a Neutral rating by Piper Sandler, targeting $60.00. CAE was initiated with a Buy rating by The Goldman Sachs Group, with a target of $33.00. Candel Therapeutics received a Buy initiation from HC Wainwright, targeting $23.00. Capricor Therapeutics was initiated at Buy by Alliance Global Partners, with a price target of $20.00. CarMax received a Buy rating from Morgan Stanley, with a price target of $80.00. Celcuity had its Buy rating reiterated by Needham & Company LLC, with a target of $29.00. Celcuity received a Buy rating from LifeSci Capital, with a target of $27.00. Cencora was rated Hold by Jefferies Financial Group, with a raised target of $300.00. Century Communities was initiated with a Buy rating by B. Riley, targeting $70.00. Chemed had its Buy rating maintained by Bank of America, though the price target was lowered from $708.00 to $650.00. Cidara Therapeutics had its Market Outperform rating reiterated by JMP Securities, with a target of $59.00. Circle Internet Group was rated Buy by Canaccord Genuity Group, with a target price of $247.00. Circle Internet Group was rated Buy by Citigroup, with a target price of $243.00. Circle Internet Group was rated Buy by Needham & Company LLC, with a target price of $250.00. Circle Internet Group was rated Hold by Deutsche Bank Aktiengesellschaft, with a target price of $155.00. Circle Internet Group was rated Market Perform by Oppenheimer (no price target provided). Circle Internet Group was rated Neutral by The Goldman Sachs Group, with a target price of $83.00. Circle Internet Group was rated Outperform by Sanford C. Bernstein, with a target price of $230.00. Circle Internet Group was rated Overweight by Barclays, with a target price of $215.00. Circle Internet Group was rated Underweight by JPMorgan Chase & Co., with a target price of $80.00. Citius Pharmaceuticals was rated Buy by D. Boral Capital, with a target of $6.00. Clene was rated Buy by D. Boral Capital, with a target price of $23.00. Cloudastructure received a Buy rating from Maxim Group, targeting $6.00. Coeur Mining was rated Buy by Roth MKM, with a target price of $12.00. Cogent Biosciences was rated Neutral by Wedbush, targeting $10.00. Cohen & Steers was initiated with an Underperform rating by Bank of America, targeting $67.00. Comfort Systems USA was rated Buy by DA Davidson, and the price target was raised to $630.00. Concentrix was rated Buy by Canaccord Genuity Group, with a price target of $80.00. Consolidated Edison was upgraded to Outperform by Mizuho, with a target of $107.00. CoreCivic received a Buy rating from Texas Capital Securities, targeting $28.00. CorMedix was downgraded to Hold by D. Boral Capital (no new price target provided). Crocs was rated Buy by Bank of America, with a reduced target of $135.00. CVS Health was rated Buy by Jefferies Financial Group, with a new target of $80.00. Dave was rated Buy by Benchmark, with a raised price target of $320.00. Dayforce was rated Buy by Needham & Company LLC, targeting $95.00. Delek US was rated Outperform by Raymond James Financial, with a price target of $23.00. Dianthus Therapeutics was assigned a Buy rating by LifeSci Capital, with a target of $45.00. DoorDash was rated Outperform by Oppenheimer, targeting $280.00. Driven Brands was initiated as Buy by BTIG Research, targeting $22.00. Duolingo was rated Buy by Evercore ISI, targeting $540.00. Dutch Bros was initiated as Outperform by CICC Research, targeting $80.00. eBay was rated Equal Weight by Wells Fargo & Company, with a new target of $66.00. Edgewise Therapeutics was initiated with a Buy rating by HC Wainwright, with a price target of $42.00. Emerson Electric Company received a Buy rating from KeyBanc, with a price target of $155.00. Etsy was rated Underweight by Wells Fargo & Company, with a raised target of $41.00. Exelixis was rated Buy by HC Wainwright, with a revised target of $53.00. Expand Energy also received a Buy rating from Mizuho Securities, with a target of $142.00. Expand Energy received a Buy rating from Citi, targeting $140.00. Expeditors International of Washington was rated Hold by Truist Financial, with a revised target of $110.00. Expro Group Holdings received a Buy rating from Wells Fargo, with a target price of $12.00. Fabrinet was rated Buy by Fox Advisors, with a target of $335.00. Federal Signal was rated Outperform by Raymond James Financial, with a raised target of $120.00. First Busey was initiated as Market Perform by Hovde Group, with a target of $25.00. First Solar received a Buy rating from Wells Fargo, with a price target of $177.00. Frequency Electronics received a Buy rating from Freedom Capital Markets, targeting $27.00. Fulcrum Therapeutics was rated Sell by BofA Securities, with a price target of $6.00. Gain Therapeutics received a Buy rating from BTIG, with a price target of $10.00. Gain Therapeutics was rated Buy by Roth MKM, with a target price of $7.00. GeneDx was rated Buy by Guggenheim, with an increased target of $115.00. Genius Sports was rated Market Outperform by JMP Securities, with a raised price target of $13.00. Genpact received a Buy rating from Needham & Company LLC, targeting $50.00. Geo Group was also rated Buy by Texas Capital Securities, with a target of $30.00. Green Brick Partners was initiated with a Neutral rating by B. Riley, with a target of $62.00. Grindr received a Market Outperform rating from JMP Securities, with a raised target of $27.00. Guaranty Bancshares was rated Overweight by Stephens, targeting $47.00. GXO Logistics was rated Hold by Truist Financial, with a revised target of $48.00. Hewlett Packard Enterprise received a Buy rating from Bank of America, with a raised target of $23.00. Hippo Holdings was rated Buy by B.Riley Financial, with a price target of $35.00. Home Depot received a Buy rating from Citi, aiming for $433.00. Home Depot received a Buy rating from Wells Fargo, with a price target of $420.00. Home Depot was rated Outperform by Telsey Advisory Group, targeting $455.00. Howmet Aerospace was rated Outperform by Royal Bank Of Canada. Hyatt Hotels also received a Buy rating from BofA Securities, targeting $150.00. Hyatt Hotels received a Hold rating from Morgan Stanley, targeting $132.00. Hyatt Hotels was rated Buy by Bernstein, targeting $167.00. Iamgold was initiated with a Market Perform rating by Raymond James Financial, targeting $8.00. Indivior was rated Buy by Craig Hallum, with a raised target of $22.00. Inmune Bio was rated Hold by BTIG, with a price target of $21.00. Inuvo received a Buy rating from HC Wainwright, with a target raised to $15.00. Ionis Pharmaceuticals was rated Buy by Barclays, targeting $57.00. It also received a target raise from Wedbush, maintaining the Outperform rating and increasing the price from $16.00 to $18.00. J.B. Hunt Transport Services was rated Hold by Truist Financial, with a new price target of $140.00. Joby Aviation was rated Buy by Canaccord Genuity, with a target of $12.00. KB Home received a Sell rating from CFRA, with a price target of $49.00. Kellanova received a Hold rating from TD Cowen, with a price target of $83.50. Kinross Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $15.00. KKR & Co. Inc. was initiated with an Overweight rating by Piper Sandler, targeting $150.00. Kratos Defense & Security Solutions was upgraded to Buy by The Goldman Sachs Group, targeting $52.00. Krystal Biotech was rated Buy by Clear Street, with a target of $190.00. Largo received a Buy rating from HC Wainwright, targeting $3.70. Lear was rated Buy by Citigroup, with a raised target of $136.00. Leonardo DRS was initiated as Buy by The Goldman Sachs Group, with a target of $49.00. Linde was upgraded to Buy by Citigroup, with a raised target of $535.00. M&T Bank was assigned a Buy rating by RBC Capital, with a target of $200.00. Marathon Petroleum was rated Strong-Buy by Raymond James Financial, with a raised target of $188.00. MasTec was rated Buy by Roth MKM, with a target of $210.00. McDonald's was rated Overweight by KeyCorp, with a revised price target of $325.00. McEwen Mining received a Buy rating from Roth MKM, with a target of $15.00. Medical Properties Trust was rated Sector Perform by Royal Bank Of Canada, with a lowered target of $4.50. Medtronic was upgraded to Peer Perform by Wolfe Research. Microsoft was reiterated with a Positive rating by UBS Group. Mister Car Wash was initiated with a Neutral rating by BTIG Research. Moderna received a Hold rating from Morgan Stanley, targeting $31.00. Neogen was rated Buy by Guggenheim, with a revised target of $10.00. New Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $4.00. Norwegian Cruise Line was rated Neutral by UBS Group, with a reduced price target of $23.00. NOV also received a Hold rating from Citi, targeting $13.00. NOV was rated Sell by Wells Fargo, with a target of $10.00. NU received an Overweight rating from JPMorgan Chase & Co., with a raised target of $16.00. Nuvalent was rated Buy by Goldman Sachs, targeting $105.00. Old Dominion Freight Line was rated Buy by Truist Financial, with an updated target of $180.00. Omeros received a Buy rating from D. Boral Capital, targeting $36.00. Omnicell was rated Buy by Wells Fargo, with a target of $37.00. Oracle also received a Buy rating from TD Cowen, targeting $250.00. Oracle received a Buy rating from Deutsche Bank, with a target of $240.00. Oracle was upgraded to Buy by Stifel Nicolaus, with a target raised to $250.00. OS Therapies was rated Buy by D. Boral Capital, with a target of $20.00. Palomar was rated Outperform by Keefe, Bruyette & Woods, with a revised target of $204.00. Par Pacific received an Outperform rating from Raymond James Financial, with a raised price target of $30.00. Parker Hannifin received a Buy rating from BofA Securities, with a target of $715.00. Pegasystems was rated Buy by Loop Capital, with an increased price target of $60.00. Planet Labs PBC was initiated with a Neutral rating by The Goldman Sachs Group, targeting $4.60. PNC Financial received a Buy rating from RBC Capital, aiming for $195.00. Porch Group received a Buy rating from B.Riley Financial, targeting $15.00. ProKidney was downgraded to Underperform by Bank of America, with a lowered target of $1.00. Protagonist Therapeutics received a Buy rating from Citi, with a price target of $72.00. Qorvo was also rated Hold by Mizuho Securities, targeting $84.00. Regeneron Pharmaceuticals was downgraded to Hold by Argus. Robinhood Markets received a Buy rating from KeyBanc, targeting $110.00. Robinhood Markets was rated Buy by Barclays, targeting $57.00. Roblox received an Overweight rating from JPMorgan Chase & Co., with a raised target of $120.00. Rocket Lab was initiated with a Neutral rating by The Goldman Sachs Group, targeting $27.00. Rocket Pharmaceuticals received a Hold rating from Morgan Stanley, with a target of $7.00. SailPoint was initiated with an Overweight rating by Cantor Fitzgerald, targeting $29.00. Schlumberger received an Overweight rating from JPMorgan Chase & Co., with a lowered target of $44.00. Schlumberger was rated Buy by Wells Fargo, targeting $43.00. SEI Investments was rated Outperform by Oppenheimer, with a raised target of $96.00. SharkNinja, Inc. was rated Buy by Jefferies, with a target of $175.00. Skyworks Solutions received a Hold rating from Mizuho Securities, with a target of $75.00. Smurfit Westrock received an Overweight rating from Barclays, with a slightly lowered target of $63.00. Southern Copper received a Hold rating from UBS, with a price target of $105.00. Starbucks was initiated with an Outperform rating by CICC Research, targeting $100.00. Stevanato Group was reiterated as Outperform by William Blair. Strategy was rated Buy by TD Cowen, targeting $590.00. Summit Therapeutics received a Buy rating from UBS, with a target of $30.00. Synopsys received a Hold rating from Wells Fargo, with a price target of $520.00. TD SYNNEX was rated Buy by Loop Capital, with an increased target of $160.00. Tempus AI was rated Buy by Guggenheim, with a raised target of $75.00. Tesla received a Buy rating from Deutsche Bank, with a price target of $345.00. Tesla was rated Buy by Morgan Stanley, with a price target of $410.00. Tesla was reiterated as Buy by Canaccord Genuity Group, with a target of $303.00. Transdigm Group was rated Buy by BofA Securities, with a price target of $1,615.00. Tronox was downgraded to Underperform by BMO Capital Markets, with a reduced target of $3.00. Tyra Bioscience was rated Buy by Oppenheimer, targeting $30.00. Unifirst received a target price of $197.00 set by Robert W. Baird. Unifirst was rated Underweight by Barclays, with a price target of $152.00. Unifirst was reiterated as Neutral by UBS Group. United Therapeutics was rated Buy by UBS Group, with a lowered target of $385.00. US Bancorp was rated Buy by RBC Capital, with a price target of $50.00. US Gold was assigned a Buy rating by Roth MKM, aiming for $18.00. Valero Energy was rated Strong-Buy by Raymond James Financial, with a raised target of $155.00. Vipshop received an Overweight rating from JPMorgan Chase & Co., with a decreased target of $18.00. Vipshop was given a Hold rating by Citi, with a target of $17.00. Virgin Galactic was initiated with a Neutral rating by The Goldman Sachs Group, targeting $3.00. Vor Biopharma was upgraded to Buy by HC Wainwright, targeting $3.00. Wabash National received a Hold rating from D.A. Davidson, with a target of $9.50. Walt Disney was upgraded to Buy by Jefferies Financial Group, with a target of $144.00. Waystar was initiated with an Outperform rating by Mizuho, targeting $48.00. Whirlpool was upgraded to Buy by Longbow Research, targeting $145.00. Wingstop was rated Buy by BTIG, with a target of $430.00. Winnebago Industries was rated Buy by Benchmark, with a reduced price target of $42.00. XPO was rated Buy by Truist Financial, with a raised target of $135.00. Zai Lab received an Outperform rating from Leerink Partners, with a revised target of $75.00. Zai Lab was assigned a Buy rating by Citi, with a target of $66.00. Zai Lab was rated Buy by Leerink Partners, with a price target of $75.00. Zynex was reiterated as Buy by HC Wainwright, targeting $8.00.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
35 minutes ago
- Globe and Mail
Kardium raises $340-million as B.C. heart device maker prepares for FDA approval, market entry
A Vancouver-area company that is poised to bring the most effective technology to market for treating a common heart problem has raised $340-million from investors. Kardium Inc., developer of a treatment for atrial fibrillation (AF), said the deal, announced Wednesday, was led by Janus Henderson Investors, sovereign wealth fund Qatar Investment Authority, MM Capital, Piper Heartland Healthcare Capital, Eventide Asset Management and Eckuity Capital. Existing backers including T. Rowe Price Investment Management Inc. and Durable Capital Partners also participated, plus an unidentified strategic investor. Hedge fund MM is the sole Canadian player in the deal. AF is an irregular heartbeat disorder that affects more than 59 million people worldwide, and causes strokes and failures. Kardium, which has previously raised more than US$300-million, is one of several players bringing devices to market that treats AF with a method called pulsed field ablation. Kardium could be poised for rapid commercial success after receiving Class 3 medical device approval from the U.S. Food and Drug Administration, which chief executive officer Kevin Chaplin said in an interview he expects this year. Few Canadian companies have received that stringent designation, reserved for devices posing the highest potential health risk. Boston Scientific Corp. generated US$1-billion in sales from its PFA device in 2024, after winning FDA approval that year. Medtronic plc, an American-Irish company, expects similar sales for its PFA product. 'This is a huge market, and it's one of the fastest-growing areas in medtech,' Mr. Chaplin said. Kardium has generated better clinical results than both rivals. In April, it published results from a study of 183 patients showing 77.8 per cent were free of AF 12 months after being treated with its technology, with no device-related 'primary safety events.' Other developers of PFA devices reported between 0.7 per cent and 2.2 per cent adverse safety events, while their treatments kept 66.7 per cent to 73.3 per cent of patients AF-free for a year. A procedure using Kardium's technology also takes less time than with competing devices. Kardium 'knocked it out of the park on that data,' said Janus portfolio manager Aaron Schaechterle in an interview. 'We think it has the strongest product in what in our opinion will be a close to US$10-billion market. The company should be able to generate its rightful share' of the category. He added that Kardium's success will 'come down to execution. It's a small company with a single product going up against some of the biggest companies in cardiology and medical technology. That challenge requires a scrappy and entrepreneurial management team, and we believe the Kardium is up to the challenge.' The 500-person company is expanding its manufacturing, now done at its facilities in Burnaby, B.C., and plans to hire hundreds of people to make and sell the product. Kardium expects to sell its devices for US$8,000 to US$10,000 each. Kardium's technology combines several existing approaches that treat different aspects of AF into a single device designed to save time and improve results. B.C. biotech boom: Vancouver looks to join the global big leagues of modern medicine The key is a three-centimetre-diameter disco ball-like globe with 122 golden, individually controlled electrodes. The sphere is flattened, encased in a sheath, inserted in a patient's femoral vein and threaded into the heart's left atrium. It is then expanded to sphere form and maps the inside of the heart to pinpoint where erratic electrical signals originate before destroying the problem cells. The device was originally designed to burn the cells using radio frequencies. But in 2021, Kardium shifted to the emerging PFA approach, whereby its device sends rapid, high voltage pulses to rupture targeted cells, restoring the heart's normal rhythms without damaging adjacent cells like the older approach. Kardium, established in 2008, grew out of conversations between Dr. Sam Lichtenstein, former head of the University of B.C.'s cardiac surgery division, and Daniel Gelbart, former chief technology officer of B.C. tech pioneer Creo Inc., whose name is on dozens of Kardium patents. Dr. Lichtenstein was frustrated by limitations of existing tools to improve patient outcomes for heart conditions. He and Mr. Gelbart, now company advisers, brainstormed ideas to fix the problem. Creo's former CEO, Amos Michelson, joined as chair to turn their ideas into a business. Former Creo employee Doug Goertzen became Kardium's first CEO (he's now president and chief operating officer). Nine years after its founding, Kardium began human trials, which were successful. But it had to do a new trial after switching to the PFA approach. Mr. Chaplin said that once Kardium gets FDA approval, it will seek approval from health authorities in Canada and Europe and aim to go public in 2026. After a three-year drought for life sciences initial public offerings, the market has started opening up, with three IPOs by medical device companies on U.S. exchanges (CeriBell, Inc. Beta Bionics Inc. and Kestra Medical Technologies, Ltd.) since last fall. David Martin, an analyst with Toronto life sciences investment bank Bloom Burton, said Kardium could also be an acquisition target. 'This has the potential to be best-in-class, which isn't always the case, therefore the potential here is substantial,' he said in an interview.
CTV News
an hour ago
- CTV News
‘Save Scott's': Mattawa residents petitions to keep discount store
Residents of the Town of Mattawa are petitioning to save Scott's Discount Store, a 20-year staple set to close in August. Eric Taschner has more.
Globe and Mail
an hour ago
- Globe and Mail
Automakers ask Carney to repeal zero-emission vehicle mandate
Auto sector chief executives urged Prime Minister Mark Carney Wednesday during a meeting on the Canada-U.S. trade war to repeal federal regulations that require one in five vehicles sold starting in 2026 to be zero-emission models. The CEOs of Ford Motor Company of Canada F-N, General Motors of Canada Co. GM-N and Stellantis Canada STLA-N met with Mr. Carney in Ottawa as the Canadian and U.S. governments try to reach a trade deal by July 21 that might end Washington's tariffs on Canadian-made automobiles, among other levies. Automakers are warning that electric-vehicle sales in Canada are waning this year and it would be impossible to reach the zero-emission vehicle (ZEV) mandate targets that take effect starting in 2026. Brian Kingston, president of the Canadian Vehicle Manufacturers' Association – which includes Ford, General Motors and Stellantis – said two key issues discussed at the meeting were trade policy and the federal ZEV sales mandate. 'At a time when the auto industry is under immense pressure, it is more important than ever that the damaging and redundant ZEV mandate be urgently removed,' Mr. Kingston said in a statement. 'Canada's longest established automakers appreciated the candid discussion with the Prime Minister and look forward to collaborating to protect and grow this critical industry,' he said. According to a controversial policy Ottawa announced in 2022, by next year 20 per cent of Canadian car sales must be powered by a battery, fuel cell or plug-in hybrid system. This rises to 60 per cent by 2030 and 100 per cent by 2035. Most automakers will miss federal EV target, expert predicts The program includes credits for manufacturers, which are earned by exceeding ZEV targets and can be banked to meet future mandates or traded. Credits are also earned by investing in charging stations. Companies that do not meet the targets fall into a deficit that must be cleared up within three years. The automakers say that missing their targets would mean limiting the availability of internal combustion vehicles to remain in compliance or purchasing credits from companies such as Tesla TSLA-Q. Automakers say they won't be able to meet next year's target, and that consumers – not government – should decide what is available on the car lots. Flavio Volpe, president of the Automotive Parts Manufacturers' Association, was not at Wednesday's meeting with Mr. Carney. But he said indications are that the trade war between Canada and the United States is hurting vehicle production in Canada. 'The half of the auto parts that leave Canadian factories, that go into Canadian assembly, those orders are down by a quarter to one third,' he said. 'There's a lot of anxiety in the business right now.' Decoder: Canada's love affair with EVs has stalled, putting Ottawa's mandate in doubt He said Ottawa shouldn't be heaping further pain on automakers who are already suffering under the Canada-U.S. strife. 'How are we going to avoid punishing the same companies who are getting punished in this trade war?' Canada is grappling with Mr. Trump's 50-per-cent tariffs on steel and aluminum, and a 25-per-cent tariff on autos. In addition, Canada faces 25-per-cent levies on anything not traded under the United States-Mexico-Canada Agreement, with the exception of oil, gas and potash, which are taxed at 10 per cent. Canada's retaliatory tariffs include levies on U.S.-made autos. Last year, EVs accounted for 13.8 per cent of total vehicles sold, according to Statistics Canada. In March of this year, EV sales fell by 45 per cent from a year ago for a total share of 6.5 per cent, driven down by the loss of provincial and federal incentives, high prices and fears over a lack of charging stations, even as overall car sales rose. Opinion: The real threat to Canada auto isn't Trump. It's our own government forcing EVs on us The federal government in January halted its EV incentives for car buyers, but says it plans to reinstate them. Under the program, car buyers received $5,000 rebates for zero-emissions vehicles and $2,500 for hybrid gas-electric vehicles. Quebec is phasing out its incentive plan while Ontario cancelled its plan in 2018. In the U.S., the world's second-largest car market, President Donald Trump eliminated the country's EV mandate and federal support for buyers. He also blocked California's efforts to mandate EV sales and set tailpipe emissions regulations. The drop in demand for EVs has prompted car makers to rethink their manufacturing and investing strategies. Honda Canada HMC-N recently postponed its $15-billion EV and battery project in Ontario, and Stellantis NV delayed production of the electric Dodge Charger R/T at its plant in Windsor, Ont. Ford Motor Co. scrubbed plans last year to make EVs in Oakville, instead planning to produce gas-powered pickup trucks when the factory reopens.
